Anti-Mouse CD40 [Clone FGK4.5] — Purified in vivo PLATINUM™ Functional Grade
Anti-Mouse CD40 [Clone FGK4.5] — Purified in vivo PLATINUM™ Functional Grade
Product No.: F1195
Clone FGK4.5 Target CD40 Formats AvailableView All Product Type Monoclonal Antibody Alternate Names Bp50, TNFRSF5 Isotype Rat IgG2a Applications Act , Agonist , FA , FC , in vivo , WB |
Antibody DetailsProduct DetailsReactive Species Mouse Host Species Rat Recommended Isotype Controls Recommended Dilution Buffer Immunogen Recombinant Mouse CD40 Fusion Protein Product Concentration ≥ 5.0 mg/ml Endotoxin Level <0.5 EU/mg as determined by the LAL method Purity ≥98% monomer by analytical SEC ⋅ >95% by SDS Page Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Pathogen Testing To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM™ antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Country of Origin USA Shipping Next Day 2-8°C RRIDAB_2830170 Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity Clone FGK4.5 recognizes an epitope on mouse CD40. Background CD40, also known as TNFSF5, is a type I transmembrane protein and member of the TNF receptor family. The binding of CD40L (CD154) on TH cells to CD40 activates antigen presenting cells and induces a variety of downstream effects (1). CD40 is expressed on B cells, dendritic cells, monocytes, thymic epithelial cells and, at low levels, on T cells (2). Signaling though CD40 plays an important role in the proliferation and differentiation of B cells and is critical for immunoglobulin (Ig) class switching (3). The membrane-anchored CD40L is expressed almost exclusively on activated CD4+ T lymphocytes. Failure to express CD40L leads to "immunodeficiency with hyper-IgM", a disease characterized by failure to produce IgG, IgA and IgE. Some of the early intracellular signaling by the CD4-CD40L system includes the association of the CD40 with TRAFs and the activation of various kinases (4). Adaptor protein TNFR2 interacts with this receptor and serves as a mediator of the signal transduction. The interaction of CD4-CD40L is found to be necessary for amyloid-beta-induced microglial activation, and thus is thought to be an early event in Alzheimer disease pathogenesis. Antigen Distribution CD40 is widely expressed on antigen-presenting cells such as dendritic cells, B cells, macrophages, and monocytes, in addition to non-immune endothelial cells, basal epithelial cells, and a variety of tumors. Ligand/Receptor CD154 (CD40L) NCBI Gene Bank ID UniProt.org Research Area Cell Biology . Costimulatory Molecules . Immunology . Neuroscience . Neuroscience Cell Markers Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. Clone FGK4.5 is an agonistic anti-mouse CD40 monoclonal antibody that has several important in vivo applications in mouse research models, primarily focused on immune system activation and modulation. Primary ApplicationsThe FGK4.5 antibody is widely used in in vivo mouse studies to activate CD40-expressing antigen-presenting cells (APCs), including B cells, dendritic cells, and macrophages. As an agonistic antibody, it mimics the natural CD40-CD154 interaction, triggering downstream immune responses without requiring the presence of CD154 ligand. Immune Cell Activation StudiesIn vivo administration of FGK4.5 leads to significant changes in immune cell populations. Studies have demonstrated that treatment with this antibody causes a substantial increase in the total number of CD8+ T cells, B220+ B cells, and CD11c+ dendritic cells in the spleen. Additionally, it promotes cell proliferation, with measurable increases in DNA synthesis among splenic B cells and T cells. This makes FGK4.5 particularly valuable for researchers studying immune cell expansion and activation dynamics. Cancer Immunotherapy ResearchAgonistic CD40 monoclonal antibodies like FGK4.5 have shown promise in anti-tumor research by activating APCs and promoting anti-tumor T cell responses. The ability to enhance immune activation against tumors makes this clone an important tool for investigating cancer immunotherapy approaches and understanding how APC activation can be leveraged for therapeutic benefit. Blocking CD40/CD154 InteractionsBeyond its agonistic properties, FGK4.5 can be used to inhibit CD40/CD154 interaction both in vitro and in vivo. This dual functionality allows researchers to study the consequences of blocking this critical co-stimulatory pathway, which is relevant for understanding autoimmune conditions and transplantation immunity. The antibody is typically administered at doses around 500 μg per injection, with treatment regimens varying based on experimental design. Commonly Used Antibodies and Proteins with FGK4.5 in the LiteratureFGK4.5 (clone name: FGK4.5 or FGK45) is a well-known agonistic anti-mouse CD40 monoclonal antibody commonly used to study immune activation, particularly in murine models. In research, FGK4.5 is often used in combination with other antibodies and proteins to assess immune cell activation, co-stimulation, and modulation of immune responses. Detection of Immune Activation and Co-StimulationWhen FGK4.5 is used to activate CD40-expressing antigen-presenting cells (APCs), researchers commonly measure downstream activation markers associated with immune cell stimulation. Some of the most frequently co-analyzed antibodies and proteins include:
These markers are typically detected using flow cytometry or other immunoassays to confirm that FGK4.5 treatment elicits a robust activation of B cells, dendritic cells, and macrophages. Functional Manipulation and Competitive InhibitionFGK4.5 is also used in assays designed to block or compete with the natural ligand, CD154 (CD40L). For example, Flag-tagged soluble CD154 (sCD154) is used in competitive binding assays to demonstrate that FGK4.5 can inhibit the interaction between CD40 and its ligand. The ability of FGK4.5 to compete with sCD154 for binding to CD40 is a common experimental endpoint, often compared to other anti-CD40 antibodies. In Vivo and Combination StudiesIn in vivo studies, FGK4.5 is sometimes used in combination with other therapeutic antibodies, such as CTLA-4 Ig, to investigate synergistic effects on immune modulation. Additionally, other anti-mouse CD40 monoclonal antibodies like 1C10 and 3/23 are frequently referenced alongside FGK4.5, especially in studies comparing the potency or mechanism of different CD40-targeting antibodies. Other Relevant Proteins
Summary Table
Key Points
This combination of tools and markers allows researchers to dissect the role of CD40 signaling in immune activation, tolerance, and therapeutic contexts. Clone FGK4.5 is a functionally active, agonistic anti-mouse CD40 monoclonal antibody that has been widely used to study immune activation, particularly of antigen-presenting cells (APCs) such as dendritic cells, B cells, and macrophages. Key findings from scientific literature incorporating citations of clone FGK4.5 include:
Summary Table of Key Findings
In summary, FGK4.5 is a central tool in mouse immunology, particularly for dissecting pathways of immune activation, APC function, macrophage polarization, and as a preclinical model for agonist CD40-based therapies. Dosing regimens for clone FGK4.5 (anti-mouse CD40 agonist antibody) vary widely based on mouse strain, disease model, administration route, and experimental objectives, with reported doses ranging from about 24 μg to 5 mg/kg per mouse per injection. Key reported regimens in literature:
Additional context and practice:
Summary Table: FGK4.5 Dosing Examples
For any specific model or application, it is essential to consult primary literature or manufacturers' dosing guides and to empirically determine optimal dosing through pilot titration. Variability in dosing reflects differences in disease mechanisms, antibody potency, administration method, and desired immunomodulatory outcomes. References & CitationsTechnical ProtocolsCertificate of Analysis |
Formats Available
Prod No. | Description |
---|---|
C2828 | |
C2829 | |
C2824 | |
C2825 | |
C2827 | |
C2826 | |
F1195 |
